Literature DB >> 1384144

Bleomycin in non-Hodgkin's lymphoma.

R A Bayer1, E R Gaynor, R I Fisher.   

Abstract

Bleomycin is a cell-cycle--specific chemotherapeutic agent, with several interesting properties, that lends itself to use in combination chemotherapeutic protocols, especially those for malignant lymphomas. In the following article, bleomycin's use as a single agent and subsequently in three generations of combination chemotherapeutic regimens is reviewed. Bleomycin's lack of myelosuppression and its tendency to concentrate in lymphoid tissue while maintaining tolerable toxicities has been the rationale for its incorporation into more aggressive treatment regimens.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1384144

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  7 in total

1.  NC1404, a novel derivative of Bleomycin with modified sugar moiety obtained during the preparation of Boningmycin.

Authors:  Xin Qi; Xinwei Wang; Hao Ren; Feng Zhang; Xiumin Zhang; Ning He; Wenqiang Guo; Ruxian Chen; Yunying Xie; Qiyang He
Journal:  J Antibiot (Tokyo)       Date:  2017-05-31       Impact factor: 2.649

2.  Crystal Structure of the Zorbamycin-Binding Protein ZbmA, the Primary Self-Resistance Element in Streptomyces flavoviridis ATCC21892.

Authors:  Jeffrey D Rudolf; Lance Bigelow; Changsoo Chang; Marianne E Cuff; Jeremy R Lohman; Chin-Yuan Chang; Ming Ma; Dong Yang; Shonda Clancy; Gyorgy Babnigg; Andrzej Joachimiak; George N Phillips; Ben Shen
Journal:  Biochemistry       Date:  2015-11-05       Impact factor: 3.162

3.  14-3-3ε boosts bleomycin-induced DNA damage response by inhibiting the drug-resistant activity of MVP.

Authors:  Siwei Tang; Chen Bai; Pengyuan Yang; Xian Chen
Journal:  J Proteome Res       Date:  2013-05-09       Impact factor: 4.466

4.  BlmB and TlmB provide resistance to the bleomycin family of antitumor antibiotics by N-acetylating metal-free bleomycin, tallysomycin, phleomycin, and zorbamycin.

Authors:  Jane M Coughlin; Jeffrey D Rudolf; Evelyn Wendt-Pienkowski; Liyan Wang; Claudia Unsin; Ute Galm; Dong Yang; Meifeng Tao; Ben Shen
Journal:  Biochemistry       Date:  2014-10-23       Impact factor: 3.162

5.  14-3-3ε mediates the cell fate decision-making pathways in response of hepatocellular carcinoma to Bleomycin-induced DNA damage.

Authors:  Siwei Tang; Huimin Bao; Yang Zhang; Jun Yao; Pengyuan Yang; Xian Chen
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240

6.  Inhibitory effect of (-)-epigallocatechin-3-gallate and bleomycin on human pancreatic cancer MiaPaca-2 cell growth.

Authors:  Sabrina Bimonte; Maddalena Leongito; Antonio Barbieri; Vitale Del Vecchio; Massimiliano Barbieri; Vittorio Albino; Mauro Piccirillo; Alfonso Amore; Raimondo Di Giacomo; Aurelio Nasto; Vincenza Granata; Antonella Petrillo; Claudio Arra; Francesco Izzo
Journal:  Infect Agent Cancer       Date:  2015-07-29       Impact factor: 2.965

Review 7.  Anticancer Activity of Bacterial Proteins and Peptides.

Authors:  Tomasz M Karpiński; Artur Adamczak
Journal:  Pharmaceutics       Date:  2018-04-30       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.